Hospital chargemaster prices for identical procedures vary by up to 18,617% between hospitals in the same county, and no patient can access these prices before receiving care

A study of hospitals in Dallas County found that chargemaster prices for identical items varied by staggering amounts: a 5-mg amlodipine tablet (a common blood pressure medication) ranged from $0.23 to $43.05 — an 18,617% difference. A partial thromboplastin time lab test ranged from $18.70 to $506.00 (2,606% difference). A circumcision ranged from $252.00 to $7,532.10 (2,889% difference). Nationally, 90th-to-10th-percentile chargemaster price ratios range from 3.2x to 11.5x for the same procedure. This matters because chargemaster prices are the starting point for what uninsured and out-of-network patients are billed. While insured patients with in-network coverage pay negotiated rates that bear little relation to the chargemaster, the approximately 27 million uninsured Americans and anyone who receives out-of-network care may be billed at or near the chargemaster rate. Even for insured patients, chargemaster prices affect out-of-pocket costs when a service is applied to a deductible or when cost-sharing is calculated as a percentage of the 'allowed amount,' which is itself derived from the chargemaster through opaque discount formulas. A patient needing a routine lab test has no practical way to learn, before the blood draw, that the same test costs $18 at Hospital A and $506 at Hospital B three miles away. This problem persists because hospitals set chargemaster prices unilaterally with no external review, no cost-justification requirement, and no legal formula. The chargemaster originated as an internal accounting tool and was never designed to be a consumer-facing price list. Hospitals have strong incentives to keep chargemaster prices high because they serve as the ceiling in negotiations with insurers — the higher the chargemaster price, the larger the 'discount' the hospital can offer while still achieving its target revenue. The price transparency rule was supposed to address this, but as noted, 65% of hospitals remain non-compliant. Even the compliant hospitals publish data in machine-readable formats that require technical expertise to access and interpret, making the data practically invisible to the average patient standing in an ER or scheduling a procedure.